The 29 portfolio companies we’ve helped build have attracted more than $2.3B of risk capital, employ close to 1,000 Canadians and have a combined value of $4B.
Our Portfolio Companies actively benefit from direct investment by adMare BioInnovations, showcasing our commitment to fostering innovative growth in the biotech sector.
KalGene is a biotechnology company developing precision medicine therapeutics designed to slow the progression of Alzheimer’s disease with an antibody-based approach